• About Stayble
  • Research
  • Media
  • Investors
  • Contact
  • sv
  • en
Stayble Therapeutics
  • About Stayble
  • Research
  • Media
  • Investors
  • Contact
  • sv
  • en

Financial Information

  1. Overview
  2. Press releases
  3. Financial Reports
  4. Financial Calendar
  5. The Share
    • Owners
    • PDMR transactions
  6. Corporate Governance
    • Board of Directors
    • Management
    • Articles of association
    • Annual Meeting 2025
    • Annual Meeting 2024
    • Annual Meeting 2023
    • Extraordinary General Meeting 2023
    • Annual Meeting 2022
    • Annual Meeting 2021
    • Annual Meeting 2020
  7. Presentations
  8. Previous issues
    • Direct Issue 2024
    • Rights Issue 2023
    • Rights Issue 2021
    • IPO 2020
      • Warrant TO1 2020
  9. IR contact

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397

Financial Reports

2024

(SV) Year-end report 2024Download
(SV) - Interim report Q3 2024Download
(SV) Half-year report 2024Download
(SV) Interim report Q1 2024Download

2023

(SV) Annual report 2023Download
Year-End report 2023 (SV)Download
Interim report Q3 2023 (SE)Download
Half-year report 2023 (SE)Download
INTERIM REPORT Q1 2023 (SE)Download

2022

Annual report 2022 (SE)Download
Interim Report Q4 - 2022 (SE)Download
INTERIM REPORT Q3 2022 (SE)Download
INTERIM REPORT Q2 2022 (SE)Download
INTERIM REPORT Q1 2022 (SE)Download

2021

Annual report 2021 (SE)Download
Bokslutskommunike 2021 Stayble Therapeutics ABDownload
INTERIM REPORT Q3 2021 (SE)Download
Interim report Q2 2021 (SE)Download
INTERIM REPORT Q1 2021 (SE)Download

2020

Annual report 2020 (SE)Download
BOKSLUTSKOMMUNIKÉ 2020 (SE)Download
INTERIM REPORT Q3 2020 (SE)Download
INTERIM REPORT Q2 2020 (SE)Download
INTERIM REPORT Q1 2020 (SE)Download

2019

Annual report 2019, English translationDownload
Bokslutskommuniké 2019 (SE)Download
Delårsrapport Q3 - 2019 (SE)Download

2018

Årsredovisning 2018 (SE)Download

2017

Årsredovisning 2017 (SE)Download

2016

Årsredovisning 2016 (SE)Download

IR Contact

M. Sc, CEO. Andreas Gerward

Andreas has during the last 10 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in economics and Venture Creation from Chalmers University of Technology.

andreas.gerward@stayble.se +46 (0)730 808 397
Stayble Therapeutics
CONTACT

Lennart Torstenssonsgatan 8
SE-412 56 Gothenburg, Sweden
info@stayble.se

Privacy policy

Menu
  • About Stayble
  • Research
  • Media
  • Investors
  • Contact
STAYBLE THERAPEUTICS

Stayble Therapeutics is a clinical pharmaceutical company developing an injection-based treatments against disc herniation. Stayble currently conducting a phase 1b within disc herniation.

To top